Insider Sell: Alector
6:14AM ET 12/15/2021 MT NewswiresShehnaaz Suliman, President and Chief Operating Officer, on December 10, 2021, sold 150,000 shares in Alector (ALEC) for $3,225,316. Following the Form 4...
Quotes Snapshot > ALEC
Alector Inc ALEC:NASDAQ
Last Price$15.54NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22
NASDAQ 15-minute delayed Bid/Ask Quotes
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$15.64 (5)
Ask (Size)$16.50 (2)
Day Low / HighN/A - N/A
Volume557.4 K
Read more news Recent News
Insider Sell: Alector
6:31AM ET 11/15/2021 MT NewswiresArnon Rosenthal, Director, Chief Executive Officer, on November 10, 2021, sold 110,000 shares in Alector (ALEC) for $2,750,000. Following the Form 4 filing...
Alector Shares AL001 Phase 2 Trial Results
3:03PM ET 11/12/2021 MT NewswiresAlector (ALEC) said Friday that its phase 2 clinical trial of AL001 showed that progranulin, a key regulator of immune activity in the brain, was restored...
Insider Sell: Alector
6:47AM ET 11/11/2021 MT NewswiresArnon Rosenthal, Director, Chief Executive Officer, on November 08, 2021, sold 200,000 shares in Alector (ALEC) for $5,000,000. Following the Form 4 filing...
View all Commentary and Analysis
Alector: The GSK Deal Is A Major Value Add
5:05PM ET 10/29/2021 Seeking AlphaCyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders
4:29PM ET 10/26/2021 Seeking AlphaHomology Medicines: In Vivo Gene Therapy Platform With Delayed Lead Trial Coming Back Online
7:00AM ET 10/22/2021 Seeking AlphaWall Street Breakfast: The Week Ahead (Podcast)
7:27AM ET 7/25/2021 Seeking AlphaCompany Profile
Business DescriptionAlector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA. View company web site for more details
| Address | 131 Oyster Point Boulevard South San Francisco, California 94080 |
| Phone | +1.415.231.5660 |
| Number of Employees | N/A |
| Recent SEC Filing | 01/05/2022 4 |
| Chief Executive Officer & Director | Arnon Rosenthal |
| President, Head-Research & Development | Saraswati Kenkare-Mitra |
| Chief Financial & Accounting Officer | Linda M. Rubinstein |
| VP-Technology & Digital Health | Charles Wolfus |
Company Highlights
| Price Open | $15.51 |
| Previous Close | $15.73 |
| 52 Week Range | $15.04 - 43.32 |
| Market Capitalization | $1.3 B |
| Shares Outstanding | 81.3 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 02/24/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.52 |
| Beta vs. S&P 500 | N/A |
| Revenue | $27.7 M |
| Net Profit Margin | -16.62% |
| Return on Equity | -12.96% |
Analyst Ratings as of 11/24/2021
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |